- Home
- LVLU vs BOLT Comparison
LVLU vs BOLT Comparison
Compare LVLU & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- BOLT
- Stock Information
- Founded
- LVLU 1996
- BOLT 2015
- Country
- LVLU United States
- BOLT United States
- Employees
- LVLU N/A
- BOLT N/A
- Industry
- LVLU Catalog/Specialty Distribution
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- BOLT Health Care
- Exchange
- LVLU Nasdaq
- BOLT Nasdaq
- Market Cap
- LVLU 18.4M
- BOLT 16.8M
- IPO Year
- LVLU 2021
- BOLT 2021
- Fundamental
- Price
- LVLU $0.28
- BOLT N/A
- Analyst Decision
- LVLU Hold
- BOLT Buy
- Analyst Count
- LVLU 2
- BOLT 3
- Target Price
- LVLU $1.00
- BOLT $50.00
- AVG Volume (30 Days)
- LVLU 778.0K
- BOLT 25.1K
- Earning Date
- LVLU 08-13-2025
- BOLT 08-12-2025
- Dividend Yield
- LVLU N/A
- BOLT N/A
- EPS Growth
- LVLU N/A
- BOLT N/A
- EPS
- LVLU N/A
- BOLT N/A
- Revenue
- LVLU $302,783,000.00
- BOLT $3,638,000.00
- Revenue This Year
- LVLU N/A
- BOLT N/A
- Revenue Next Year
- LVLU $2.53
- BOLT $24.14
- P/E Ratio
- LVLU N/A
- BOLT N/A
- Revenue Growth
- LVLU N/A
- BOLT N/A
- 52 Week Low
- LVLU $0.22
- BOLT $5.20
- 52 Week High
- LVLU $1.88
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- LVLU 34.10
- BOLT 47.22
- Support Level
- LVLU $0.22
- BOLT $5.52
- Resistance Level
- LVLU $0.56
- BOLT $6.21
- Average True Range (ATR)
- LVLU 0.09
- BOLT 0.32
- MACD
- LVLU -0.02
- BOLT 0.05
- Stochastic Oscillator
- LVLU 15.25
- BOLT 60.22
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.